RE: Letter to Coughlin4 Mar 2025 13:14
Personally the one thing I wanted was to know why AS left. (Because it is never a positive for the SP when the CEO leaves unexpectedly)
I think/guess it can only be for "bad" reasons. ie better to take a hit on the SP and get him out.
I am not sure it was the last raise at 50p, maybe it was the straw and and the camel, but there seemed too much time gone by and once it was done, well it was done and the cash was raised and on we go.
The DX division, well, again that is meant to be cash neutral now and even more time had elapsed so I can't see that being the reason, (Ie what does avct get out of it for the disruption of the ceo leaving), except for maybe they said it had to be sold and he said it would show him in such a very light he felt he had to resign? Its possible.
The last reason I can think of is that the bigger shareholders lost confidence in his ability to take the trial forward. That, to me, is the worst case scenario, because it meant they stoped trusting what he said. and therefore maybe the trial results have been over hyped or manipulated to show a biased result. They have never been peer reviewed and the SP has never reacted positively to an update, so there is for me anyway, some circumstantial evidence that might support that guess.
Look, I don't know if P1b dosing has started or not, I don't think anyone here knows, but in any event its March 2025 and there are a lot of guesses going on because we have very little definitive knowledge.
As I have said before, it does not have to be ambiguous, it is a clear decision the BoD make when they word RNS's. So when its open to interpretation then that's a red flag, (or should be) for investors.
Yes AIM is not the Pi's friend, thats very true, but it is difficult imo to lay the SP decline over the last 4 years at the door of MM's, bed wetters, shorters and the like.
The SP in hindsight usually tells the story, just like a who-dun-it, sometimes you don't have to wait to the final reel to see who did, in fact do it...